Under the agreement, PCAS will be responsible for
manufacturing foscarnet sodium hexahydrate, the API contained
in Clinigen's Foscavir, while Clinigen will leverage its own
infrastructure and global network of partners to supply the
medicine to hospitals worldwide.
Clinigen holds marketing authorizations to sell Foscavir as a
treatment for HIV/AIDS?related cytomegalovirus (CMV)
infections and herpes in 16 markets, as well as in bone
marrow transplantation in Japan. Clinigen is working with
medicines regulatory agencies to secure licenses to market
Foscavir in additional markets, including the US in Q1
2012.
Anton Jenkins, Chief Operating Officer of Clinigen
Healthcare, commented: "PCAS has an impeccable track record
in the area of API manufacturing, with strong technical
capabilities and robust compliance systems, making the
company an ideal partner for Clinigen. We are confident that
PCAS and Clinigen will together ensure the continued
availability of Foscavir wherever it is needed. Our agreement
underlines Clinigen Group's mission to get the right drug to
the right patient at the right time."
Didier Combis, Head of the Exclusive Synthesis business unit
at PCAS, said:
"We are delighted to be working with Clinigen and its team of
experienced managers. The company's streamlined structure
allows for very short response times, a key requirement in
the low?volume, specialist?supply drugs business. This
agreement makes a perfect fit for PCAS. We will rely on our
dedicated site in France for the production of starting
material and our world?class facilities in Finland for the
manufacture of injectable APIs."
Clinigen Healthcare is part of Clinigen Group, a fast?growing specialty pharmaceutical and pharma services business formed by merger in 2010. Clinigen Healthcare acquires or in?licenses mature or end?of?lifecycle products for development and commercialization in hospitals. Clinigen Healthcare's core therapeutic areas include oncology, leukemia, hematology, transplantation, virology, pain management and critical care. The company also looks to acquire products that it can develop and commercialize in orphan indications.
Clinigen Group is headquartered in Burton?on?Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan. For more information visit: www.clinigengroup.com.
About PCAS
PCAS is a Euronext compartiment C?listed company specializing
in the production of specialty chemicals and active
pharmaceutical ingredients for life sciences customers. It
develops, manufactures and markets complex molecules and
competitive industrial
solutions for the global healthcare, cosmetic and material
science industries, with a focus on
quality, innovation, safety and sustainability. For more
information visit: www.pcas.com.
Foscavir (foscarnet sodium) is licensed to treat
cytomegalovirus (CMV) retinitis in HIV patients and
acyclovir?resistant mucocutaneous herpes simplex virus (HSV)
infections in immunocompromized patients in: Australia,
Belgium, France, Germany, Hungary, Israel, Italy, Japan,
Luxembourg, Mexico, the Netherlands, New Zealand, Singapore,
Spain, Switzerland and the UK. In July 2011, the Japanese
Ministry of Health Labor and Welfare (MHLW) approved Foscavir
for the treatment of CMV in hematopoietic stem cell
transplant patients.
For more information visit:
www.medicines.org.uk/EMC/company/3129/Clinigen%20Healthcare%20Ltd
distribué par | Ce noodl a été diffusé par PCAS SA et initialement mise en ligne sur le site http://www.pcas.fr. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-06 09:50:26 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Clinigen and PCAS sign long-term supply agreement |